Search clinical trials for: telmisartan, valsartan

Total 771 results

Boehringer Ingelheim
Bayer; GlaxoSmithKline

Completed

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Hypertension

United States, Canada
Korea University Anam Hospital

Completed

Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Coronary Artery Disease | Hypertension | Diabetes

Korea, Republic of
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

Hypertension

United States
Boehringer Ingelheim

Completed

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Hypertension | Diabetes Mellitus, Type 2

Taiwan, Korea, Republic of, United States, New Zealand, Australia, Argentina, Canada, Mexico
Boehringer Ingelheim

Completed

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

Hypertension

United States
Brigham and Women's Hospital

Active, not recruiting

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Frailty | Heart Failure, Systolic

United States
Boehringer Ingelheim

Completed

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

Hypertension
Boehringer Ingelheim

Completed

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Hypertension | Diabetic Nephropathies

Spain, Taiwan, Malaysia, Italy, Portugal, France, Czech Republic, Korea, Republic of, Russian Federation, Denmark, Germany, Slovakia, Ukraine
Boehringer Ingelheim

Completed

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Hypertension
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Hypertension

Romania
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Boehringer Ingelheim

Completed

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Hypertension
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Boehringer Ingelheim

Completed

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Diabetic Nephropathies

Japan
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis (ESPRIT)

Hypertension
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Laboratorio Elea Phoenix S.A.
Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBA

Completed

Telmisartan for Treatment of COVID-19 Patients

COVID-19 Drug Treatment

Argentina
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Chronic Heart Failure
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Boehringer Ingelheim

Completed

Telmisartan in Mild to Moderate Hypertensive Patients

Hypertension
Novartis Pharmaceuticals

Completed

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Heart Failure

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Hannover Medical School
DLR German Aerospace Center

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure (ARNI-Sy)

Heart Failure

Germany
LanZhou University

Unknown

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Hypertension
Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
The Children's Hospital of Zhejiang University...

Unknown

Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules

Henoch Schönlein Purpura Nephritis

China
Kitakyushu-Tsuyazaki Hospital

Completed

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

Hypertension

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
Boehringer Ingelheim

Completed

Micardis®. Observational Study in Patients With Essential Hypertension

Hypertension
Bio-innova Co., Ltd

Not yet recruiting

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Healthy Subjects

3

Subscribe